CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

By Dennis Thompson HealthDay ReporterTUESDAY, June 24, 2025 (HealthDay News) — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to blockbuster drugs Ozempic /Wegovy and ...

A GLP-1 medication used to treat type 2 diabetes and obesity may help cut a person's monthly migraine days by about half, a ...

Key Takeaways A new drug combo can help prevent muscle loss on GLP-1 drugsCombining bimagrumab with semaglutide caused 93% of weight loss to come from fat aloneBy comparison, about 72% of weight loss ...

Patients who took a GLP-1 drug fared better than those in a control group at keeping their blood glucose levels in a healthy ...

Shiru is inviting partners to harness its AI-powered ingredient discovery platform to explore ingredients that naturally ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA ...